| |
Colorectal cancer (CRC) is still the second leading
cancer killer in the US, affecting both men and women
equally. But by using Hemoccult annual screening tests,
the risk of death from CRC can be reduced by up to
33%.1 Hemoccult products are the only FOBTs proven
through large-scale, randomized clinical studies to
reduce both CRC incidence and mortality.
Used with confidence by physicians
for over 30 years, Hemoccult products are supported
in over 300 clinical publications and are recommended
by the American Cancer Society as an effective screening
method. Our annual triple-slide, take-home FOBT is
the least invasive colorectal cancer screening method
available and can be prepared by the patients in the
privacy of their own home. With fewer diet restrictions
than other FOBT products, Hemoccult is easier for
the patient to complete.
|
